Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events

Keyphrases

• Adverse Events 100%
• Treatment Failure 100%
• Immunogenicity 100%
• Anti-drug Antibodies 100%
• Anti-TNF Drugs 100%
• Failure Event 100%
• Secondary Failure 37%
• Clinical Practice 12%
• Treatment Efficacy 12%
• Rheumatoid Arthritis Patients 12%
• Therapeutic Drug Monitoring 12%
• Effective Strategies 12%
• Neutralizing Capacity 12%
• Expert Opinion 12%
• Monoclonal Antibody 12%
• Self-antigens 12%
• Area Cover 12%
• Therapeutic Management 12%
• Immunological Mechanisms 12%
• Anti-tumor Necrosis Factor (anti-TNF) 12%
• Remission Rate 12%
• Biological Agents 12%
• Fusion Protein 12%
• Therapeutic Benefits 12%
• Immunogenic 12%
• Immune-mediated Inflammatory Diseases 12%
• Genetic Engineering 12%
• Biological Drugs 12%
• Non-self 12%
• Immunological Tests 12%
• Antibody Protein 12%
• Drug Therapeutics 12%
• Opinion Monitoring 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Tumor Necrosis Factor 100%
• Adverse Event 100%
• Immunogenicity 100%
• Drug Antibody 100%
• Biological Product 50%
• Cytokine 12%
• Disease 12%
• Combination Therapy 12%
• Rheumatoid Arthritis 12%
• Inflammatory Disease 12%
• Therapeutic Drug Monitoring 12%
• Remission 12%
• Monoclonal Antibody 12%
• Immunoglobulin 12%
• Fusion Protein 12%

Immunology and Microbiology

• Tumor Necrosis Factor 100%
• Immunogenicity 100%
• Drug Antibody 100%
• Biological Product 50%
• Cytokine 12%
• Inflammatory Arthritis 12%
• Inflammatory Disorder 12%
• Monospecific Antibody 12%
• Monoclonal Antibody 12%